References
- Ali H, Shirode AB, Sylvester PW, Nazzal S. (2010). Preparation, characterization, and anticancer effects of simvastatin–tocotrienol lipid nanoparticles. Int J Pharm, 389, 223–231.
- Almeida AJ, Runge S, Muller RH. (1997). Peptide-loaded solid lipid nanoparticles: influence of production parameters. Int J Pharm, 149, 255–265.
- Babbar AK, Kashyap R, Chauhan UP. (1991). A convenient method for the preparation of 99mTc-labelled pentavalent DMSA and its evaluation as a tumor imaging agent. J Nucl Bio Med, 35, 100–104.
- Bhavsar MD, Tiwari SB, Amiji MM. (2006). Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. J Control Release, 110, 422–430.
- Bolton S, Bon C. (2004). Pharmaceutical Statistics: Practical and Clinical Application, 4th ed. New York: Marcel Dekker.
- Derakhshandeh K, Erfan M, Dadashzadeh S. (2007). Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: factorial design, characterization and release kinetics. Eur J Pharm Biopharm, 66, 34–41.
- Freitas C, Muller RH. (1998). Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle dispersions. Int J Pharm, 168, 221–229.
- Goodman, and Gilman’s (2006). The Pharmacological basis of Therapeutics, 10th ed. Hardman JG, Limbird LE, Eds. New York: McGraw-Hill.
- Leroux JC, Allemann E, Doelker E, Gurny R. (1994). New approach for the preparation of nanoparticles by an emulsification-diffusion method. Eur J Pharm Biopharm, 41, 14–18.
- Maaßen S, Schwarz C, Mehnert W, Lucks JS, Yunis-Specht F, Muller BW, Muller RH. (1993). Comparison of cytotoxicity between polyester nanoparticles and solid lipid nanoparticles. Proc Int Symp Control Rel Bioact Mater, 20, 490–491.
- Manjunath K, Reddy JS, Venkateswarlu V. (2005). Solid lipid nanoparticles as drug delivery systems. Methods Find Exp Clin Pharmacol, 27, 127–144.
- Margulis-Goshen K, Magdassi S. (2009). Formation of simvastatin nanoparticles from microemulsion. Nanomedicine, 5, 274–281.
- Mehnert W, Mäder K. (2001). Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev, 47, 165–196.
- Mishra P, Babbar A, Chauhan UP. (1991). A rapid instant thin layer chromatographic procedure for determining radiochemical purity of 99Tcm-IDA agents. Nucl Med Commun, 12, 467–469.
- Mukherjee S, Ray S, Thakur RS. (2007). The current status of solid lipid nanoparticles. Pharmbit, XV, 53–60.
- Muller RH, Maaßen S, Weyhers H, Specht F, Lucks JS. (1996). Cytotoxicity of magnetite loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles. Int J Pharm, 138, 85–94.
- Müller RH, Mäder K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur J Pharm Biopharm, 50, 161–177.
- Nastruzzi C. (2005). Lipospheres in Drug Targets and Delivery. New York: CRC Press.
- Nezasa K, Higaki K, Matsumura T, Inazawa K, Hasegawa H, Nakano M, Koike M. (2002). Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab Dispos, 30, 1158–1163.
- Nishioka Y, Yoshino H. (2001). Lymphatic targeting with nanoparticulate system. Adv Drug Deliv Rev, 47, 55–64.
- Schubert MA, Müller-Goymann CC. (2003). Solvent injection as a new approach for manufacturing lipid nanoparticles—evaluation of the method and process parameters. Eur J Pharm Biopharm, 55, 125–131.
- Shah M, Pathak K. (2010). Development and statistical optimization of solid lipid nanoparticles of simvastatin by using 23 full factorial design. AAPS Pharm Sci Tech, [online 23 March 2010%%Ea.
- Suresh G, Manjunath K, Venkateswarlu V, Satyanarayana V. (2007). Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS PharmSciTech, 8, 24.
- Theobald AE. (1990). Textbook of Radiopharmacy: Theory and Practice. Sampson CB, Ed. Gordon and Breach New York.
- Vanderbast F, Sereno A, Bauduer P. (2007). Oral pharmaceutical composition containing a statin derivative. US Patent 4667088.
- Yang S, Zhu J, Lu Y, Liang B, Yang C. (1999). Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res, 16, 751–757.
- Zhang D, Tan T, Gao L. (2003). Preparation of oridonin-loaded solid lipid nanoparticles and studies on them in vitro and in vivo. Nanotechnology, 17, 5821–5828.